Skip to content
Peptide Evidence Registry

Comparison Centre

Two compounds, the same questions, no cherry-picking

Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.

Sharing keeps the two compounds you picked.

How to read these scores

Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.

  • Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
  • Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
  • Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
  • Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
  • Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.

None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.

SLU-PP-915

A small-molecule research chemical — not a peptide — that activates the ERR nuclear receptors and increased running capacity in mice. No human data.

L2Animal / lab studiesResearch / unapproved supply
Full profile

AOD-9604

A growth-hormone fragment marketed for fat loss whose own obesity trials failed to establish a benefit.

L2Animal / lab studiesNot approved for this use
Full profile

How far human research has progressed

SLU-PP-915

Preclinical only — animal and cell work, no human study identified

AOD-9604

Reached Phase 2b in obesity; development discontinued without an established benefit

Claim-specific benefit evidence

A human exposure study or trial registration does not establish that the claimed benefit occurs.

SLU-PP-915

Not separately assessed; see the full profile.

AOD-9604

Not separately assessed; see the full profile.

Human research context

SLU-PP-915

Preclinical only — animal and cell work, no human study identified

AOD-9604

Reached Phase 2b in obesity; development discontinued without an established benefit

Human efficacy evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

SLU-PP-915

Strength of the human efficacy evidence0 of 100 evidence strength

AOD-9604

Strength of the human efficacy evidence12 of 100 evidence strength

Preclinical (animal / lab) evidence strength

Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.

SLU-PP-915

Strength of the animal and lab evidence40 of 100 evidence strength

AOD-9604

Strength of the animal and lab evidence40 of 100 evidence strength

Human safety evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

SLU-PP-915

Strength of the human safety evidence3 of 100 evidence strength

AOD-9604

Strength of the human safety evidence15 of 100 evidence strength

Regulatory status (legal position, not proof it works)

SLU-PP-915

Check jurisdiction-specific details in the profile.

Not an approved medicine anywhere and not established in human trials in our curated record. It exists as a laboratory tool compound; anything sold under the name is unapproved research material.

AOD-9604

Check jurisdiction-specific details in the profile.

Not an approved medicine for weight loss or anything else in any major region. FDA compounding material notes limited safety information. It is sold widely as a research chemical and heavily discussed in fat-loss communities. It is also prohibited in sport.

Common claims

SLU-PP-915

  • · Exercise in a capsule
  • · Fat loss and endurance gains without training
  • · Mitochondrial rejuvenation

AOD-9604

  • · Targeted fat loss without growth hormone side effects
  • · Works because it is 'the fat-loss part of HGH'
  • · Cartilage and joint repair

How settled our evidence rating is

SLU-PP-915

Very low confidence in ratingL2Animal / lab studies

AOD-9604

Very low confidence in ratingL2Animal / lab studies

Cancer-related questions raised by the biology

These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.

SLU-PP-915

Not established. ERR signalling has been studied in tumour biology in both directions, and no human data exist for this compound, so we make no claim either way.

AOD-9604

No established human cancer signal specific to this fragment. Growth-hormone-axis concerns discussed for full growth hormone do not transfer automatically to a fragment with no established receptor activity.

What this adds up to, in plain English

SLU-PP-915

The interesting work is in animals and lab studies. Treating it as an established human treatment is not supported by evidence.

AOD-9604

The interesting work is in animals and lab studies. Treating it as an established human treatment is not supported by evidence.

A comparison is not a recommendation

Neither column here is an endorsement, and the compound with the higher numbers is not the “better” or “safer” one — it is simply the one with more or better-quality research behind it. Two compounds can both be poorly evidenced, and better-evidenced says nothing about whether either is a sensible idea for a specific person. That is a conversation for a qualified clinician.